Bladder Cancer: Symptoms, Diagnosis and Treatment
Bladder cancer most often begins in the urothelial lining of the bladder. The classic symptom is visible blood in the urine, often painless and intermittent. Cystoscopy is used to look directly inside the bladder, and transurethral resection of bladder tumour (TURBT) removes tissue to establish the cancer type, grade and depth of invasion. The most important early distinction is whether the tumour is non-muscle-invasive — limited to the lining or lamina propria — or muscle-invasive. Non-muscle-invasive disease is commonly treated with TURBT plus risk-adapted intravesical therapy such as chemotherapy or BCG. Muscle-invasive disease usually requires radical cystectomy with systemic therapy or, in selected patients, bladder-preserving trimodality treatment.
What is bladder cancer?
Most bladder cancers are urothelial carcinomas, which arise from cells lining the bladder and the rest of the urinary collecting system. Less common types include squamous-cell carcinoma, adenocarcinoma and small-cell/neuroendocrine cancer. Histological subtype matters because treatment can differ.
What symptoms can bladder cancer cause?
- Visible blood in urine — the most important warning symptom.
- Microscopic blood found on urine testing.
- Urinary frequency, urgency or burning, particularly when repeated cultures do not explain the symptoms.
- Pelvic pain, flank pain, weight loss or leg swelling in more advanced disease.
Blood may appear once and then disappear. A clear urine sample a few days later does not rule out a bladder tumour.
Who is at higher risk?
- Cigarette, bidi or other tobacco smoking — the most important preventable risk factor.
- Increasing age.
- Certain occupational exposures to aromatic amines and industrial chemicals.
- Previous pelvic radiotherapy or long-term exposure to selected chemotherapy drugs.
- Chronic bladder irritation in particular settings.
- Personal history of urothelial cancer, because bladder and upper-tract urothelium can develop new tumours over time.
How is bladder cancer diagnosed?
Urine tests
Urinalysis confirms haematuria and checks for infection. Urine cytology can detect high-grade urothelial cancer and carcinoma in situ better than low-grade tumours, so a negative cytology does not exclude bladder cancer.
Cystoscopy
A flexible cystoscope passes through the urethra and allows direct inspection of the bladder lining. If a suspicious tumour is seen, TURBT is arranged.
Imaging
Upper-tract imaging assesses the kidneys and ureters because urothelial tumours can occur elsewhere. CT urography is commonly used when detailed evaluation is required.
TURBT
TURBT removes all visible tumour where feasible and samples the underlying bladder wall. The pathology report should state grade, stage and whether muscularis propria (detrusor muscle) is present and involved.
Stage: the key treatment divide
| Category | What it includes | Why it matters |
|---|---|---|
| Non-muscle-invasive bladder cancer (NMIBC) | Ta, T1 and carcinoma in situ (CIS) | Usually managed with TURBT plus intravesical therapy and cystoscopic surveillance; risk of recurrence and progression varies widely. |
| Muscle-invasive bladder cancer (MIBC) | T2 or greater invasion into bladder muscle and beyond | Needs staging for spread and usually definitive treatment such as radical cystectomy or selected trimodality bladder preservation. |
| Metastatic bladder cancer | Distant lymph nodes or organs | Systemic therapy is central; modern regimens include chemotherapy, immunotherapy and antibody-drug conjugates/targeted therapy in appropriate settings. |
How is non-muscle-invasive bladder cancer treated?
TURBT is the foundation. A second TURBT may be required when the first resection was incomplete, when high-grade T1 disease is present, or when adequate muscle was not sampled in a setting where staging could be underestimated. After TURBT, treatment is based on recurrence/progression risk.
- Low-risk disease may receive a single immediate intravesical chemotherapy instillation after TURBT when safe.
- Intermediate-risk disease may receive a course of intravesical chemotherapy or BCG depending on features.
- High-risk disease commonly receives BCG induction plus maintenance if the bladder is being preserved.
- Very-high-risk or BCG-unresponsive disease may require discussion of early radical cystectomy or alternative bladder-preserving systemic/intravesical options when cystectomy is unsuitable or declined.
How is muscle-invasive bladder cancer treated?
For fit patients, cisplatin-based neoadjuvant chemotherapy followed by radical cystectomy and pelvic lymph-node dissection is a standard curative pathway. In selected patients with appropriate tumour characteristics and a functional bladder, maximal TURBT followed by combined chemotherapy and radiation — trimodality therapy — can preserve the bladder. Treatment choice should be multidisciplinary.
Urinary diversion after cystectomy
Removing the bladder requires another way for urine to leave the body. Common options include an ileal conduit with a stoma and external bag, or an orthotopic neobladder connected to the urethra in selected patients. Continent cutaneous reservoirs are used less often. The safest diversion depends on kidney function, bowel health, urethral status, dexterity, motivation and cancer factors.
Follow-up and recurrence
Bladder cancer has a strong tendency to recur, especially NMIBC. Cystoscopy schedules are therefore risk-based and can continue for years. High-risk disease also needs upper-tract imaging and cytology in selected follow-up plans. Smoking cessation remains important after diagnosis because ongoing smoking increases risk of recurrence and other cancers.
When to seek urgent care
Heavy bleeding with clots, inability to pass urine, fever with obstruction, severe flank pain, dizziness or fainting require urgent assessment. After TURBT or intravesical therapy, high fever or systemic illness also needs prompt medical attention.
How to read a TURBT pathology report
The pathology after TURBT determines the next branch of treatment. Ta means a papillary tumour confined to the inner lining. T1 means tumour has invaded the connective tissue beneath the lining but not the bladder muscle. Carcinoma in situ (CIS) is a flat high-grade lesion. T2 means invasion into muscularis propria — the bladder muscle — and changes the disease to muscle-invasive bladder cancer.
The report should also state low grade or high grade and, for many T1/high-grade resections, whether detrusor muscle is present in the specimen. If muscle is absent when it is needed for reliable staging, or if high-grade T1 disease is found, a repeat TURBT may be recommended. Lymphovascular invasion, variant histology and concomitant CIS can further increase risk and may alter the discussion toward earlier radical treatment.
Why risk groups matter in non-muscle-invasive bladder cancer
NMIBC is not one low-risk disease. Recurrence risk and progression risk are estimated from stage, grade, tumour size, number of tumours, previous recurrence rate, CIS and other pathological features. A small solitary low-grade Ta tumour may need TURBT with limited intravesical treatment and relatively less intense surveillance. High-risk or very-high-risk disease can require repeat resection, BCG with maintenance and, in selected patients, discussion of radical cystectomy before muscle invasion develops.
Living after bladder-cancer treatment
Follow-up can be long because urothelial cancer has a tendency to recur. Cystoscopy is central after bladder-preserving treatment. After radical cystectomy, life changes depend on the urinary diversion: an ileal conduit requires stoma care, while a neobladder requires training, scheduled voiding and sometimes intermittent catheterisation. Sexual function, kidney function, vitamin B12 and metabolic issues may also need attention depending on surgery and bowel segment used.
Staging before major bladder-cancer treatment
When muscle-invasive disease is diagnosed, cross-sectional imaging of the chest, abdomen and pelvis is used to look for lymph-node or distant spread and to assess the upper urinary tracts. Kidney function, blood count, nutritional status and general fitness help determine whether cisplatin-based chemotherapy and major surgery are safe. If bladder preservation is being considered, tumour size and location, hydronephrosis, CIS, bladder function and the completeness of TURBT all matter. A treatment plan should therefore follow complete staging rather than the TURBT label alone.
The TURBT report is the turning point in bladder-cancer care
Before TURBT, cystoscopy may strongly suggest bladder cancer, but the pathology after resection determines the actual branch of treatment. Stage (Ta, T1, CIS or muscle invasion), grade, presence of detrusor muscle, lymphovascular invasion and variant histology can change what happens next. A tumour that looks small endoscopically can still be high grade, and a large papillary tumour can still be non-muscle-invasive.
For this reason, patients should ask for the written pathology report rather than relying only on “the tumour was removed.” In bladder cancer, the operation and the pathology are inseparable parts of the diagnosis.
Consultation checklist
- Cystoscopy and TURBT operative notes.
- Histopathology report showing stage, grade and whether detrusor muscle is present.
- CT urography or staging CT/MRI images and reports.
- Urine cytology if done.
- Previous BCG or intravesical chemotherapy dates and number of instillations.
- Smoking history.
- Kidney function and major medical conditions.
- Current medicines, especially anticoagulants.
FAQs
Is bladder cancer always caused by smoking?
No, but tobacco is the strongest preventable risk factor. Many patients have never smoked.
Can bladder cancer be cured?
Many non-muscle-invasive and localized muscle-invasive cancers are curable. Cure probability depends on stage, grade, response to treatment and overall health.
Why do I need repeated cystoscopies after TURBT?
Because bladder tumours can recur elsewhere in the bladder even after a complete initial resection.
Does high-grade mean muscle-invasive?
No. Grade describes how abnormal the cells look; stage describes depth. A high-grade tumour can still be non-muscle-invasive, but its progression risk is higher.
Can bladder cancer be treated without removing the bladder?
Yes. Most NMIBC is treated without cystectomy. Selected MIBC can also be managed with trimodality bladder-preserving therapy, but careful selection and lifelong surveillance are essential.
Related reading
- Painless Blood in Urine: Why It Matters
- Cystoscopy for Bladder Cancer
- TURBT Surgery Explained
- Low-Grade vs High-Grade Bladder Cancer
- Non-Muscle Invasive Bladder Cancer
- Muscle-Invasive Bladder Cancer
- BCG Therapy for Bladder Cancer
- Radical Cystectomy Explained
- Urologist in Latur
References
- European Association of Urology (EAU). EAU Guidelines on Non-Muscle-Invasive Bladder Cancer. 2026 edition https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer
- European Association of Urology (EAU). EAU Guidelines on Muscle-Invasive and Metastatic Bladder Cancer. 2026 edition https://uroweb.org/guidelines/muscle-invasive-and-metastatic-bladder-cancer
- National Cancer Institute. Bladder Cancer Treatment (PDQ®)–Patient Version https://www.cancer.gov/types/bladder/patient/bladder-treatment-pdq
- American Urological Association/SUO. Non-Muscle Invasive Bladder Cancer Guideline (2016; amended 2024) https://www.auanet.org/guidelines-and-quality/guidelines/bladder-cancer-non-muscle-invasive-guideline
- American Urological Association/ASCO/ASTRO/SUO. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer Guideline (2017; amended 2024) https://www.auanet.org/guidelines-and-quality/guidelines/muscle-invasive-bladder-cancer